Kamada Ltd. (NASDAQ: KMDA) is a globally integrated biopharmaceutical company focused on the development, manufacturing, and commercialization of specialty plasma-derived protein therapeutics. Utilizing advanced protein purification technologies, the company markets a portfolio of proprietary products for rare and severe conditions, including Alpha-1 Antitrypsin Deficiency, alongside a robust distribution network for secondary healthcare products.